Effects of Vacuum Compression Therapy on Healing of Chronic Lower Limb Ulcers: A Randomised Controlled Study Authors: Lenka Krupová, Miroslav Koliba, Yvetta Vantuchová, Vladimír Jetmar, Martin Olšar, Jakub Muťka, Michaela Nejedlá Published: 2026 ABSTRACT ABSTRACTChronic lower limb ulcers remain difficult to manage when unresponsive to conventional treatment. This study evaluated the clinical and physiological effects of vacuum compression therapy on wound healing and quality of life. Fifty patients with chronic lower limb ulcers were randomised to receive 12 sessions of vacuum compression therapy plus standard care or standard care alone over 4 weeks. Wound dimensions, exudate, pain intensity and quality of life were assessed at baseline and post‐treatment. Estimated wound volume was calculated as length × width × depth. Tissue oxygenation was measured at the dorsum of the foot in the experimental group. The vacuum compression therapy group showed greater improvements in wound width, depth, volume and quality of life. Estimated wound volume decreased by 61% in the intervention group, whereas no statistically significant volume reduction was observed in controls. Local tissue oxygenation in the experimental group increased by 43%. Baseline wound size was associated with poorer quality of life. Vacuum compression therapy may enhance wound healing and quality of life in patients with chronic lower limb ulcers. Observed increases in local tissue oxygenation represent exploratory physiological findings within the treated cohort that warrant controlled comparative evaluation. Trial Registration: ClinicalTrials.gov identifier: NCT07737184. Introduction Chronic lower limb ulcers are commonly defined as wounds located below the knee that fail to heal within four to 6 weeks despite appropriate treatment [1, 2]. They affect approximately 1%–3% of the adult population, with prevalence increasing markedly with age and exceeding 5% among individuals over 80 years. It is estimated that up to 10% of the population will develop a chronic wound during their lifetime, with a wound‐related mortality rate of approximately 2.5% [3]. Chronic lower limb ulcers have a heterogeneous aetiology. The most common causes include venous insufficiency, arterial disease, neuropathic and diabetic mechanisms, as well as mixed vascular factors. While venous ulcers typically affect the lower leg, neuropathic ulcers are more frequently located on the foot [4]. In addition to advanced age, established risk factors for venous leg ulcers include a family history of venous disease, female sex, history of deep vein thrombosis or phlebitis, previous leg injury, chronic leg edema, sedentary lifestyle and prolonged standing. In contrast, arterial leg ulcers are commonly associated with diabetes mellitus, hypertension, hyperlipidemia, obesity and smoking. Additional risk factors typical for foot ulcers include peripheral neuropathy with loss of protective sensation, limited joint mobility and anatomical deformities [5]. Standard of care varies according to ulcer aetiology and clinical presentation. Appropriate wound management typically includes debridement and tailored dressings. In venous ulcers, these measures are complemented by leg elevation and compression therapy; arterial ulcers often require revascularization strategies, whereas neuropathic ulcers necessitate off‐loading to reduce mechanical stress [6]. Despite adequate treatment, a substantial proportion of patients remain non‐responders. Approximately 25%–50% of leg ulcers and more than 30% of foot ulcers fail to achieve complete healing within 6 months of treatment [5]. Recurrence rates are also high, particularly in venous disease, where up to 80% of ulcers recur after initial healing [7]. Tissue oxygenation and microcirculation play a central role in the wound healing process, regardless of ulcer aetiology. Adequate oxygen delivery through the microvascular network supports essential reparative mechanisms, including cellular proliferation, angiogenesis, collagen synthesis and resistance to infection [8, 9]. Conversely, tissue hypoxia has been consistently associated with impaired healing and wound chronicity. Therapeutic strategies aimed at improving local oxygen availability and restoring microcirculatory function may therefore enhance healing potential in chronic wounds [10, 11]. Given the importance of tissue oxygenation and microcirculation in wound repair, therapeutic approaches aimed at improving local perfusion may represent a valuable adjunct to standard care. One modality that has gained increasing attention in recent years is vacuum compression therapy (VCT). This technique is based on the cyclic alternation of negative (underpressure) and positive (overpressure) pressure phases applied to the affected limb. Such alternating pressure is presumed to enhance venous return during the positive‐pressure phase and stimulate arterial inflow during the negative‐pressure phase, thereby improving local blood flow and tissue oxygenation [12, 13]. During treatment, the distal part of the lower limb is placed within a sealed chamber connected to a pressure‐regulating device. The controlled alternation of pressure phases induces dynamic changes in limb perfusion, which may contribute to enhanced periwound circulation and support wound healing processes [12]. Although the perfusion‐enhancing effects of VCT have been relatively well described in hemodynamic studies, clinical evidence supporting its role in the treatment of chronic wounds remains limited. To date, only one randomised controlled trial has evaluated the clinical effects of VCT on lower limb ulcer healing [14]. However, this study primarily assessed wound size reduction and time to healing and did not comprehensively evaluate broader clinical outcomes such as tissue oxygenation, pain or quality of life. Consequently, the current evidence base remains restricted, with most available studies consisting of small clinical trials and hemodynamic investigations focusing predominantly on perfusion parameters rather than multidimensional patient‐centred outcomes. This randomised controlled trial aimed to comprehensively evaluate the clinical impact of VCT in patients with chronic lower limb wounds in comparison with standard wound care alone. The primary outcome was change in estimated wound volume. Secondary outcomes included wound dimensions, exudate, pain intensity, tissue oxygenation and health‐related quality of life. Furthermore, the study explored associations between objective clinical parameters and patient‐reported outcomes and examined the correlation between wound severity and its overall burden on patients' daily functioning and quality of life. The trial also aimed to document treatment tolerability and any adverse events associated with VCT. Methods Study Design This study was designed as a prospective, exploratory, parallel‐group randomised controlled trial. The study included patients with chronic lower limb ulcers unresponsive to conventional treatment. Participants were randomised to either an experimental group receiving vacuum compression therapy in addition to standard care or a control group receiving standard care alone. The study protocol was approved by the institutional ethics committee (approval number: 271/2024). All procedures were conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants prior to enrollment. This exploratory randomised study was retrospectively registered in the ClinicalTrials.gov registry (protocol ID: NCT07737184). The study protocol and statistical analysis plan are available from the corresponding author upon reasonable request. The study was conducted and reported in accordance with the CONSORT 2010 guidelines for randomised controlled trials [15]. No important changes to the trial protocol, prespecified outcomes or statistical analyses were made after trial commencement. Participants The study included adult patients (≥ 18 years) with chronic lower limb ulcers of ischemic, venous, diabetic or post‐traumatic aetiology that had persisted despite appropriate standard therapy and showed no significant signs of healing progression over a one‐month period. Ulcer aetiology was determined based on clinical examination and relevant diagnostic findings. Patients were required to be in stable general condition and capable of providing written informed consent. Exclusion criteria comprised age under 18 years, inability to cooperate with study procedures, clinically significant infection requiring systemic antibiotic therapy, active oncological disease, severe uncontrolled pain and contraindications to vacuum compression therapy, including severe uncorrected critical limb ischemia. Vascular assessment was performed as part of the eligibility evaluation to identify clinically relevant arterial insufficiency and contraindications to VCT. Patients and the public were not involved in the design, conduct, reporting or dissemination planning of this trial. Intervention and Randomization After enrollment and immediately following written informed consent, participants were assigned to the intervention or control group in a 1:1 ratio using simple randomization based on the outcome of a point‐of‐care dice roll administered dynamically without advance sequence generation. Participants were enrolled by the treating clinical team and group assignment was performed by a study investigator not involved in outcome assessment. No stratification or blocking was applied and no formal allocation concealment mechanism was implemented. Participants allocated to the experimental group underwent VCT using the vacuum‐compression device (BTL Industries Ltd., Prague, Czech Republic) in addition to standard wound care. VCT was administered by placing the affected lower limb within the sealed transparent chamber over the standardised primary and secondary wound dressings. Therapy was administered three times per week (Monday, Wednesday and Friday) over a four‐week period, resulting in a total of 12 sessions. The duration of each procedure ranged from 20 to 30 min. VCT was applied exclusively to the affected limb. During treatment, the affected lower limb was positioned within a sealed transparent cylindrical chamber connected to a pressure‐regulating system. VCT consisted of cyclic alternation between positive (overpressure) and negative (underpressure) phases. Pressure parameters were selected according to the manufacturer's recommendations for venous lower limb ulcers and adjusted within predefined clinical limits based on individual tolerance and clinical presentation. Positive pressure typically ranged between approximately 6–8 kPa and negative pressure between −4 and −8 kPa. The duration of individual pressure phases allowed for at least 10 alternating cycles during each session. Throughout each procedure, the treated limb was visually monitored through the transparent chamber to assess vascular reactivity and treatment tolerance. Transient changes in skin coloration during pressure alternation were observed as indicators of peripheral perfusion response. If necessary, minor adjustments of pressure phase duration were performed within protocol‐defined safety limits. Patients were continuously monitored for discomfort, pain or any adverse reactions. Because all procedures were conducted within a specialised hospital‐based wound care facility, immediate medical assistance was readily available throughout the entire treatment session. No separate standardised adverse‐event checklist was used. Patient safety was regularly monitored in accordance with the clinical and study protocol before, during and after each treatment session by qualified healthcare professionals. Clinically relevant findings or complications were documented in the medical and study records and managed according to their severity. To ensure consistency of treatment conditions, all participants received standardised wound management. Wounds were cleansed using a hypochlorous irrigation solution, followed by application of a wound gel when indicated. A silver‐containing hydrofiber dressing was used as the primary dressing. For heavily exuding wounds, the hydrofiber dressing with silver was applied alone; for mildly to moderately exuding wounds, it was combined with cleansing gel. The same type of secondary dressing was used in all cases. Thus, the only difference between the study groups was the application of vacuum compression therapy. Due to the nature of the intervention, participants and care providers were aware of group assignment. Outcome assessors were also aware of group assignment. Outcome Measures The primary outcome was change in estimated wound volume. Wound length, width and depth were measured using a single‐use paper ruler. Each wound was photographed with a measurement scale placed adjacent to the lesion to allow independent verification of wound dimensions. Estimated wound volume was calculated as the product of wound length, width and depth (Volume = length × width × depth), providing an approximate three‐dimensional assessment of wound size. Secondary outcomes included wound dimensions, pain intensity, wound exudate, quality of life and tissue oxygenation. All outcomes were assessed at baseline before randomization and again after completion of the 4‐week treatment period. Pain intensity was assessed using a 10‐point numeric rating scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Wound exudate was evaluated using a semi‐quantitative 4‐point scale (0 = none, 1 = mild, 2 = moderate, 3 = heavy exudation). Quality of life was assessed using the 17‐item Wound‐QoL questionnaire. Each item is scored on a 5‐point Likert scale (0–4), with higher scores indicating worse quality of life. The total score represents the mean of all items and ranges from 0 to 4. A responder analysis based on the minimal clinically important difference (MCID) was performed for Wound‐QoL. A reduction of ≥ 0.5 points in the total score was considered clinically meaningful improvement, based on previously published interpretability thresholds for this instrument [16]. The Wound‐QoL was used in its validated Czech version. Permission for its use was obtained from the original authors. Tissue oxygenation was measured as transcutaneous oxygen partial pressure (TcPO2), expressed in mmHg. Measurements were performed at the dorsum of the affected foot to assess local perfusion and at the subclavian region as a systemic reference site. The subclavian measurement served to distinguish local perfusion changes from potential systemic alterations in oxygenation. To ensure that positive Δ values consistently reflect clinical improvement across all endpoints, Δ was defined as baseline minus post‐treatment value for wound dimensions, volume, exudate, pain (NRS) and wound‐QoL and as post‐treatment minus baseline value for TcPO2. Percentage changes were derived from these directionally standardised change scores for descriptive and graphical presentation. Statistics Given the limited prior evidence regarding the clinical effects of VCT in patients with chronic lower limb ulcers, this study was designed as an exploratory randomised trial. No formal a priori sample size calculation was performed. The target sample size of 50 participants was determined pragmatically based on the expected clinical capacity and eligible patient volume at the participating centre during the planned recruitment period. This cohort size was intended to provide preliminary estimates of treatment effects and their accompanying 95% confidence intervals to evaluate estimate precision and to inform future adequately powered trials. All statistical analyses were performed using R software (R Foundation for Statistical Computing, Vienna, Austria; version 4.5.2). Distribution of continuous variables was assessed using the Shapiro–Wilk test. Within‐group comparisons (baseline vs. post‐treatment) were performed using paired t‐tests for normally distributed variables and Wilcoxon signed‐rank tests for non‐normally distributed variables. Between‐group comparisons of change from baseline were conducted using the Mann–Whitney U test for all outcomes. This approach was chosen due to the presence of non‐normal distributions and outliers in several variables and to ensure methodological consistency across outcomes. Differences between groups are presented as Hodges–Lehmann estimates with corresponding 95% confidence intervals (CI). Effect sizes were calculated using Cliff's delta (δ). To adjust for baseline imbalances in wound volume, an analysis of covariance (ANCOVA) was additionally conducted on post‐treatment wound volume using baseline volume as a covariate. A two‐sided p‐value < 0.05 was considered statistically significant. Additional exploratory analyses included responder analysis for Wound‐QoL based on the MCID threshold and correlation analyses between selected objective and patient‐reported outcomes. Given the exploratory pilot design of this study, secondary outcomes and correlation analyses were conducted without formal adjustments for multiple comparisons. All p‐values reported for secondary endpoints and exploratory correlations are therefore considered nominal (with nominal significance set at p < 0.05) and should be interpreted as hypothesis‐generating. No interim analyses or formal stopping guidelines were planned. Analyses were performed on a complete‐case basis and included all participants who completed the treatment protocol and follow‐up assessment. No imputation of missing data was performed. Graphical summaries of change scores and percentage changes were based on participants with complete paired measurements. An artificial intelligence‐based language tool was used for language editing and stylistic improvement of the manuscript. The authors take full responsibility for the content. Results Participant recruitment took place between July 2024 and December 2025, with overall trial conduct, including treatment interventions and post‐treatment assessments, completed in December 2025. Of the 50 enrolled patients, 48 completed the treatment protocol and were included in the final analysis (Figure 1). Two patients from the experimental group were excluded prematurely because they did not complete the intervention and post‐treatment assessment. All participants in the control group completed the planned standard care protocol, while 23 of 25 participants in the experimental group completed all scheduled VCT sessions. Baseline demographic and clinical characteristics of the study participants are summarised in Table 1. Overall, the therapy was well tolerated and no serious adverse events or treatment‐related complications were observed in either group. No adverse events leading to treatment discontinuation were recorded. CONSORT 2010 flow diagram of participant recruitment, allocation, follow‐up and analysis. TABLE 1Baseline characteristics of participants.Experimental group (n = 25)Control group (n = 25)Age (years)61.24 ± 15.0769.84 ± 11.85Female sex, n (%)8 (32%)12 (48%)Ulcer aetiology, n (%)Venous14 (56%)16 (64%)Post‐traumatic4 (16%)2 (8%)Ischemic2 (8%)4 (16%)Diabetic5 (20%)3 (12%) Note: Data are presented as mean ± standard deviation (SD) or number (percentage). Baseline characteristics of participants. Note: Data are presented as mean ± standard deviation (SD) or number (percentage). Changes in clinical parameters assessed at baseline and after completion of the treatment programme are summarised for the experimental and control groups in Tables 2 and 3, respectively. In the experimental group, statistically significant within‐group improvements were observed across all monitored outcomes except for subclavian TcPO2. In contrast, within the control group, statistically significant improvements were limited to wound depth, exudate and pain intensity. Although baseline estimated wound volume appeared numerically higher in the experimental group than in the control group (3.20 vs. 1.44 cm3), the between‐group comparison did not demonstrate a statistically significant difference at baseline (Mann–Whitney U test, p = 0.212). TABLE 2Summary of assessed parameters before (Pre) and after (Post) the treatment programme in the experimental group.Experimental group (n = 23)Pre b Post b Percentage change c p d Wound length (cm)3.50 (3.50)3.00 (2.70)23.06% ± 25.29%< 0.001Wound width (cm)2.00 (1.80)1.80 (1.95)27.11% ± 23.12%< 0.001Wound depth (cm)0.20 (0.40)0.20 (0.25)41.27% ± 29.51%< 0.001Estimated wound volume (cm3)3.20 (8.07)1.44 (3.37)61.22% ± 26.98%< 0.001Exudate1.00 (1.00)1.00 (1.00)17.39% ± 41.89%0.03NRS3.00 (3.00)2.00 (3.00)40.53% ± 38.21%< 0.001TcPO2‐foot a 31.22 ± 18.6635.74 ± 20.6242.60% ± 88.86%0.03TcPO2‐subclavian a 88.48 ± 29.1489.39 ± 26.7911.31% ± 55.24%0.903WQL a 2.15 ± 0.811.41 ± 0.8234.56% ± 31.58%< 0.001Abbreviations: NRS, numeric rating scale; TcPO2, transcutaneous oxygen partial pressure; WQL, wound‐QoL questionnaire. a Variables are presented as mean ± standard deviation (SD) due to normal distribution. b Data are presented as median (interquartile range [IQR]) unless otherwise stated. c Percentage changes are reported as mean ± SD and were calculated as the average change across individual participants within each group. Positive values indicate clinical improvement and negative values indicate worsening. d Within‐group comparisons were performed using paired t‐tests for normally distributed variables and Wilcoxon signed‐rank tests for non‐normally distributed variables. p‐value < 0.05 was considered statistically significant. Summary of assessed parameters before (Pre) and after (Post) the treatment programme in the experimental group. Abbreviations: NRS, numeric rating scale; TcPO2, transcutaneous oxygen partial pressure; WQL, wound‐QoL questionnaire. Variables are presented as mean ± standard deviation (SD) due to normal distribution. Data are presented as median (interquartile range [IQR]) unless otherwise stated. Percentage changes are reported as mean ± SD and were calculated as the average change across individual participants within each group. Positive values indicate clinical improvement and negative values indicate worsening. Within‐group comparisons were performed using paired t‐tests for normally distributed variables and Wilcoxon signed‐rank tests for non‐normally distributed variables. p‐value < 0.05 was considered statistically significant. TABLE 3Summary of assessed parameters at baseline (Pre) and after (Post) completion of the treatment programme in the control group.Control group (n = 25)Pre b Post b Percentage change c p d Wound length (cm)3.50 (3.20)2.10 (4.50)10.18% ± 40.87%0.199Wound width (cm)2.00 (1.80)1.80 (1.95)2.12% ± 56.07%0.204Wound depth (cm)0.20 (0.30)0.20 (0.20)3.00% ± 62.58%0.035Estimated wound volume (cm3)1.44 (3.28)1.05 (2.88)−23.97% ± 183.57%0.273Exudate2.00 (1.00)1.00 (1.00)7.33% ± 17.40%0.037NRS3.00 (4.00)2.00 (3.00)35.19% ± 41.76%0.004WQL a 1.84 ± 0.941.62 ± 0.913.73% ± 68.05%0.151Abbreviations: NRS, numeric rating scale; WQL, wound‐QoL questionnaire. a Variables are presented as mean ± standard deviation (SD) due to normal distribution. b Data are presented as median (interquartile range [IQR]) unless otherwise stated. c Percentage changes are reported as mean ± SD and were calculated as the average change across individual participants within each group. Positive values indicate clinical improvement and negative values indicate worsening. d Within‐group comparisons were performed using paired t‐tests for normally distributed variables and Wilcoxon signed‐rank tests for non‐normally distributed variables. p‐value < 0.05 was considered statistically significant. Summary of assessed parameters at baseline (Pre) and after (Post) completion of the treatment programme in the control group. Abbreviations: NRS, numeric rating scale; WQL, wound‐QoL questionnaire. Variables are presented as mean ± standard deviation (SD) due to normal distribution. Data are presented as median (interquartile range [IQR]) unless otherwise stated. Percentage changes are reported as mean ± SD and were calculated as the average change across individual participants within each group. Positive values indicate clinical improvement and negative values indicate worsening. Within‐group comparisons were performed using paired t‐tests for normally distributed variables and Wilcoxon signed‐rank tests for non‐normally distributed variables. p‐value < 0.05 was considered statistically significant. Between‐group comparisons of change from baseline for all outcomes are presented in Table 4. The unadjusted primary‐outcome analysis favoured the experimental group for estimated wound volume (p = 0.020). Nominally significant between‐group differences were also observed for wound width, wound depth and quality of life. When adjusting for baseline wound volume using an analysis of covariance (ANCOVA), the treatment effect approached statistical significance (F = 3.74, p = 0.059). Complete wound closure during the 4‐week study period was achieved in 2 patients (8.7%) in the experimental group compared with 0 patients (0.0%) in the control group. TABLE 4Between‐group differences in change from baseline (Δ) with 95% confidence intervals and effect sizes.Δ experimental (n = 23) a Δ control (n = 25) a Between‐group Δ (95% CI) b Effect size c p d Wound length (cm)0.50 (0.80)0.20 (0.90)0.30 (−0.10, 0.70)0.2140.202Wound width (cm)0.70 (0.70)0.10 (0.40)0.50 (0.20, 0.90)0.5220.002Wound depth (cm)0.10 (0.25)0.00 (0.20)0.10 (0.00, 0.200)0.3670.026Estimated wound volume (cm3)1.45 (3.43)0.30 (1.31)1.65 (0.23, 3.93)0.3950.02Exudate0.00 (1.00)0.00 (0.00)0.00 (−0.00, 0.00)0.1220.369NRS1.00 (1.00)0.00 (2.00)0.00 (−1.00, 1.00)0.0350.833WQL0.71 (0.59)0.18 (0.71)0.53 (0.18, 0.88)0.4620.014Abbreviations: Δ, change from baseline; CI, confidence interval; NRS, numeric rating scale; WQL, wound‐QoL questionnaire. a Data are presented as median (interquartile range [IQR]). Positive values indicate clinical improvement and negative values indicate worsening. b Differences are presented as Hodges–Lehmann estimates with 95% confidence intervals. c Effect sizes are reported as Cliff's δ. d Between‐group comparisons were performed using the Mann–Whitney U test. p‐value < 0.05 was considered statistically significant. Between‐group differences in change from baseline (Δ) with 95% confidence intervals and effect sizes. Abbreviations: Δ, change from baseline; CI, confidence interval; NRS, numeric rating scale; WQL, wound‐QoL questionnaire. Data are presented as median (interquartile range [IQR]). Positive values indicate clinical improvement and negative values indicate worsening. Differences are presented as Hodges–Lehmann estimates with 95% confidence intervals. Effect sizes are reported as Cliff's δ. Between‐group comparisons were performed using the Mann–Whitney U test. p‐value < 0.05 was considered statistically significant. Graphical summaries of change scores for selected outcomes are provided as box plots in Figures 2, 3, 4. Percentage changes in TcPO2 measured at the dorsum of the affected foot and at the subclavian reference site are illustrated in Figure 5. While TcPO2 at the foot demonstrated improvement following treatment, TcPO2 measured at the subclavian region showed minimal change. Change from baseline in estimated wound volume in the experimental and control groups. Boxes represent the interquartile range (IQR), horizontal lines indicate medians, whiskers denote minimum and maximum values and crosses represent mean values. The p‐value corresponds to the between‐group comparison of change from baseline. Change from baseline in wound width in the experimental and control groups. Boxes represent the interquartile range (IQR), horizontal lines indicate medians, whiskers denote minimum and maximum values and crosses represent mean values. The p‐value corresponds to the between‐group comparison of change from baseline. Change from baseline in wound‐QoL questionnaire (WQL) scores in the experimental and control groups. Boxes represent the interquartile range (IQR), horizontal lines indicate medians, whiskers denote minimum and maximum values and crosses represent mean values. The p‐value corresponds to the between‐group comparison of change from baseline. Percentage change in transcutaneous oxygen partial pressure (TcPO2) at the dorsum of the foot and the subclavian region in the experimental group. Boxes represent the interquartile range (IQR), horizontal lines indicate medians, whiskers denote minimum and maximum values and crosses represent mean values. A responder analysis based on the MCID for Wound‐QoL score (defined as a ≥ 0.5‐point reduction in the total score) showed that clinically meaningful improvement was achieved in 65% of patients in the experimental group compared with 36% in the control group (p = 0.043). The odds of achieving a clinically meaningful improvement were higher in the experimental group (OR 3.33, 95% CI 1.02–10.88). An example of wound size changes in a representative patient from the experimental group is presented in Figure 6. Representative clinical photographs of a venous lower limb ulcer in the experimental group at baseline (a) and after 4 weeks of vacuum compression therapy (b). Exploratory correlation analyses identified several nominally significant associations between subjective and objective measures, including relationships between select baseline wound characteristics (particularly estimated wound volume) and quality of life, as well as between pain intensity and quality of life (Table 5). A nominally significant association was also observed between change in pain intensity and change in tissue oxygenation. The relationship between estimated wound volume and Wound‐QoL score is graphically illustrated in Figure 7. TABLE 5Exploratory Spearman correlations between selected baseline and change variables.Target variableCorrelated parameterExperimental group (n = 23)Control group (n = 25) p b rs p b rsWQL (Pre)Wound length (Pre)0.0510.4110.0500.396Wound width (Pre)0.0920.3600.1130.325Wound depth (Pre)0.0700.3840.0300.435Estimated wound volume (Pre)0.0500.4140.0080.521NRS (Pre)0.0070.5440.0030.572NRS (Δ)TcPO2‐foot (Δ) a 0.041−0.429NANAAbbreviations: NRS, numeric rating scale; rs, Spearman correlation coefficient; TcPO2, transcutaneous oxygen partial pressure; WQL, wound‐QoL questionnaire. a Correlations involving TcPO2 were calculated in the experimental group only. b Correlation analysis was performed using Spearman correlation (rs). p‐values were not adjusted for multiple comparisons and should be interpreted as nominal (with nominal significance set at p < 0.05). Each row represents an individual pairwise correlation between the listed Target Variable and the Correlated Parameter. Exploratory Spearman correlations between selected baseline and change variables. Abbreviations: NRS, numeric rating scale; rs, Spearman correlation coefficient; TcPO2, transcutaneous oxygen partial pressure; WQL, wound‐QoL questionnaire. Correlations involving TcPO2 were calculated in the experimental group only. Correlation analysis was performed using Spearman correlation (rs). p‐values were not adjusted for multiple comparisons and should be interpreted as nominal (with nominal significance set at p < 0.05). Each row represents an individual pairwise correlation between the listed Target Variable and the Correlated Parameter. Association between baseline wound‐QoL questionnaire (WQL) score and estimated wound volume at baseline. The dotted red line represents the fitted regression line. The Spearman correlation coefficient (rs) and corresponding p‐value are shown in the figure. Discussion This randomised exploratory study suggests that the addition of VCT to standard wound care may lead to greater reductions in wound dimensions and estimated wound volume, as well as greater improvements in quality of life, compared with standard treatment alone. The combined approach also demonstrated potential in enhancing local tissue oxygenation. In contrast to the subclavian reference site, a statistically significant increase in TcPO2 was observed at the dorsum of the affected foot, suggesting a localised perfusion effect within the experimental group. Although reductions in wound length, exudate and pain intensity were numerically greater in the experimental group, these differences did not reach statistical significance in between‐group comparisons. This may suggest that both treatment strategies contribute similarly to improvements in these particular outcomes. Exploratory correlation analyses indicated nominally significant associations between objective wound characteristics and patient‐reported outcomes. A nominally significant relationship between baseline wound volume and quality of life was observed, supporting the expected assumption that greater tissue damage is associated with poorer quality of life. Similarly, baseline pain intensity was nominally associated with quality of life scores. In contrast to static baseline measurements, the exploratory correlation between change in pain reduction (pre‐treatment minus post‐treatment NRS) and change in tissue oxygenation (post‐treatment minus pre‐treatment TcPO2) revealed a nominally significant inverse correlation (rs = −0.429, p = 0.041). This inverse relationship indicates that patients with the largest gains in microvascular oxygenation reported comparatively smaller reductions in pain intensity. From a pathophysiological standpoint, several mechanisms may account for this inverse finding. First, rapid oxygenation recovery and microvascular reperfusion in chronically ischemic tissues can induce transient hyperemic sensation or nociceptive sensitization (“reperfusion distress”) [17, 18]. Second, patients with the most severe baseline microvascular compromise had the greatest numerical capacity for oxygenation gains. However, pain in chronic lower limb ulcers has a complex, multifactorial aetiology, encompassing neuropathic, inflammatory and mechanical factors, which may not resolve synchronously with short‐term microvascular improvements [19, 20]. Nevertheless, this finding should be interpreted with caution, as it may have been influenced by the relatively small sample size of the experimental group and the generally low, discrete baseline pain values, factors that limit the sensitivity of correlation analyses and increase susceptibility to statistical variability. The limited availability of studies specifically investigating VCT in chronic lower limb ulcers restricts direct quantitative comparison of treatment effects. Nevertheless, the findings of the present study are broadly consistent with existing evidence suggesting beneficial effects of VCT on wound healing and local perfusion. Akbari et al. conducted a randomised controlled trial in 18 patients with diabetic foot ulcers and demonstrated a statistically significant improvement in wound area in the experimental group compared with standard care, with a 25% reduction in wound area versus 8% in the control group after 10 treatment sessions [14]. Although differences in study population and outcome measures preclude direct comparison, these findings support the potential role of VCT in enhancing wound healing dynamics. Similarly, Khadir et al. reported improvements in microcirculatory parameters following combined VCT and standard care in patients with diabetes [13]. The observed increase in local TcPO2 in the present study is in line with these findings and further supports the hypothesis that VCT may enhance tissue perfusion at the treated site. Several limitations should be acknowledged. First, the relatively small sample size limits the generalizability of the findings and the precision of effect size estimates. Second, the study was not blinded due to logistical constraints in routine hospital practice and allocation concealment was not formally implemented during the point‐of‐care dice‐roll randomization procedure. Although both VCT and standard wound care were standardised and delivered according to predefined protocols, the absence of blinding and the lack of a sham VCT intervention may have influenced patient‐reported outcomes such as pain intensity and quality of life, as well as unblinded outcome assessments. Furthermore, tissue oxygenation was measured only in the experimental group. While the subclavian region served as an internal reference site to distinguish local from systemic effects, the subclavian site constitutes an internal reference within treated patients rather than a between‐group comparator; without corresponding TcPO2 measurements in the control group, the study cannot exclude the possibility that foot TcPO2 improves partly as a non‐specific response to standard wound care and healing over time. Although wound volume estimation based on length × width × depth is a practical and commonly used clinical method, it provides an approximate measure and may be less accurate in irregularly shaped wounds. Furthermore, baseline median wound volume was numerically greater in the experimental group than in the control group. Although this difference was not statistically significant, this baseline imbalance may have influenced the unadjusted estimates of treatment effect and should be considered when interpreting the outcomes. In addition, ulcer aetiology was categorised based on the predominant clinical feature in patients who frequently presented with mixed vascular etiologies; subtle baseline imbalances in aetiology distribution across small study arms may therefore represent a potential source of residual confounding. Finally, while adverse events were monitored through direct clinical observation and patient self‐report rather than a formal structured checklist, all procedures were conducted under continuous oversight by specialised clinical staff who evaluated patients at every treatment session, ensuring robust safety monitoring. Nevertheless, the absence of a standardised log may limit the systematic capture of mild or transient subjective symptoms and the absence of long‐term follow‐up precludes conclusions regarding the durability of the observed improvements. The generalisability of these findings is primarily limited to patients with chronic lower limb ulcers unresponsive to standard care and treated in a hospital‐based setting. As the majority of included ulcers were of venous origin, caution is warranted when extrapolating the results to other aetiologies. The applicability of these findings is likely greatest in settings where VCT is delivered using similar treatment protocols and in combination with standardised wound care. Future research should extend beyond addressing the limitations of the present study and focus on evaluating the effects of VCT across different ulcer etiologies and baseline patient characteristics. Specifically, future multi‐centre randomised controlled trials should incorporate centralised allocation concealment, blinded outcome assessment, standardised wound measurement procedures and dual‐arm microvascular monitoring to confirm treatment‐specific perfusion changes. Properly designed multivariable analyses may help identify clinical and perfusion‐related predictors of treatment response and contribute to the development of predictive models capable of identifying patients most likely to benefit from VCT, as well as potential non‐responders. Further investigation into the optimization of VCT parameters, including pressure settings and cycle characteristics, may support refinement and standardisation of treatment protocols according to ulcer aetiology and baseline clinical status. In addition, comparative studies evaluating VCT alongside currently recommended standard therapies, such as compression therapy for venous ulcers, would help clarify the positioning of VCT within contemporary wound management strategies. The present study should be interpreted as an exploratory randomised investigation. Preliminary evidence suggests that vacuum compression therapy may positively influence both objective wound healing parameters and patient‐reported outcomes in chronic lower limb ulcers. By combining morphological assessment, TcPO2 monitoring and quality‐of‐life evaluation, this study offers a multidimensional perspective on treatment response. Vacuum compression therapy demonstrated potential as an exploratory adjunct to standard wound care in patients with chronic lower limb ulcers. The therapy was associated with greater reductions in wound dimensions and improvements in quality of life compared with standard treatment alone. While localised increases in foot tissue oxygenation were detected at the treated site, prospective controlled studies with dual‐arm oxygenation monitoring are required to confirm whether these physiological changes are specific to VCT. Funding The study received no external grant funding for its conduct. BTL Industries Ltd. (Prague, Czech Republic) provided administrative support for retrospective trial registration and agreed to cover the open‐access article processing charge (APC) for this publication. The manufacturer had no role in the study design, data collection, statistical analysis, interpretation of the results, manuscript preparation or the decision to submit the manuscript for publication. Ethics Statement The study protocol was approved by the institutional ethics committee of University Hospital Ostrava (approval number: 271/2024). Consent Written informed consent was obtained from all participants prior to enrollment. Conflicts of Interest The authors disclose administrative and publication support from BTL Industries Ltd., the manufacturer of the device evaluated in this study, as detailed in the Funding section. The authors declare no other Conflicts of Interest.